Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database

References

• Roux J, Guilleux A, Lefort M, et al. Use of healthcare services by patients with multiple sclerosis in France over 2010–2015: a nationwide population-based study using health administrative data. Mult Scler J Exp Transl Clin. 2019;5(4):205521731989609. .
   Google Scholar
• Foulon S, Maura G, Dalichampt M, et al. Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. J Neurol. 2017;264::1185–1192.
   PubMed Web of Science ®Google Scholar
• Multiple sclerosis international federation. Atlas of MS 2013 - Mapping multiple sclerosis around the world [Internet]. London, UK: Multiple sclerosis international federation; 2014. 28. Available from: http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report
   Google Scholar
• Iacobaeus E, Arrambide G, Amato MP, et al. Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult Scler. 2020 Jun 12;26(9):1352458520925369. DOI:https://doi.org/10.1177/1352458520925369.
   Google Scholar
• Arrambide G, Iacobaeus E, Amato MP, et al. Aggressive multiple sclerosis (2): treatment. Mult Scler. 2020 Jun 12;26(9):1352458520924595. DOI:https://doi.org/10.1177/1352458520924595.
   Google Scholar
• Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215–224.
   PubMed Web of Science ®Google Scholar
• Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273–279.
   PubMedGoogle Scholar
• Fattore G, Lang M, Pugliatti M. The Treatment experience, burden, and unmet needs (TRIBUNE) study - measuring the socioeconomic consequences of multiple sclerosis. Mult Scler. 2012;18:5–6.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19:e11–25.
   PubMedGoogle Scholar
• Lebrun-Frenay C, Kobelt G, Berg J, et al. European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for France. Mult Scler. 2017;23:65–77.
   PubMed Web of Science ®Google Scholar
• Raimundo K, Tian H, Zhou H, et al. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv Res. 2013;13:131.
   PubMed Web of Science ®Google Scholar
• Lefeuvre D, Rudant J, Foulon S, et al. Healthcare expenditure of multiple sclerosis patients in 2013: a nationwide study based on French health administrative databases. Mult Scler J Exp Transl Clin [Internet]. 2017 3, [cited 2017 Oct 6]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600306/
   PubMedGoogle Scholar
• Kobelt G, Thompson A, Berg J, Group the MS, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J [Internet]. SAGE PublicationsSage UK: London, England; 2017 [cited 2020 Sep 11]; Available from: https://journals.sagepub.com/doi/10.1177/1352458517694432?icid=int.sj-related-articles.similar-articles.16
   Google Scholar
• Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Revue d’Épidémiologie et de Santé Publique. 2017;65:S149–67.
   PubMed Web of Science ®Google Scholar
• Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954–962.
   PubMed Web of Science ®Google Scholar
• Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78:161–175.
   PubMed Web of Science ®Google Scholar
• Centre des liaisons européennes et internationales de sécurité sociale, République Française. The French Social Security System. I-Health, maternity, paternity, disability, and death [Internet]. Vous informer sur la protection sociale à l’international. 2020 [cited 2020 Oct 12]. Available from: https://www.cleiss.fr/docs/regimes/regime_france/an_1.html
   Google Scholar
• Heinzlef O, Molinier G, van Hille B, et al. Economic burden of the out-of-pocket expenses for people with multiple sclerosis in France. Pharmaco Economics Open [Internet]. 2020 cited 2020 Sep 24. DOI:https://doi.org/10.1007/s41669-020-00199-7.
   Google Scholar
• Chevreul K, Berg Brigham K, Durand-Zaleski I, et al. France: health system review. Health Syst Transit. 2015;17:1–218,xvii.
   PubMedGoogle Scholar
• Arrêt maladie [Internet]. [cited 2020 Sep 15]. Available from: https://www.ameli.fr/assure/remboursements/indemnites-journalieres/arret-maladie
   Google Scholar
• Pensions d’invalidité [Internet]. [cited 2020 Sep 15]. Available from: https://www.ameli.fr/entreprise/vos-salaries/montants-reference/pension-invalidite
   Google Scholar
• Detournay B, Debouverie M, Pereira O, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019;36:101396.
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120, SAGE Publications Ltd STM
   PubMed Web of Science ®Google Scholar
• Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: comparison between centre-based and local service healthcare delivery. PLOS ONE. 2019 Sep 19;14(9):e0222012. DOI:https://doi.org/10.1371/journal.pone.0222012.
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18:7–15.
   PubMed Web of Science ®Google Scholar
• Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–647.
   PubMedGoogle Scholar
• Chevalier J, Chamoux C, Hammès F, et al. Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a French societal perspective. Ramagopalan SV, editor. PLoS ONE. 2016;11:e0150703.
   PubMed Web of Science ®Google Scholar
• Petruzzo M, Palladino R, Nardone A, et al. The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;38:101514.
   PubMed Web of Science ®Google Scholar
• Bosco-Lévy P, Debouverie M, Brochet B, et al. Validation d’un algorithme complexe d’identification de poussées dans la sclérose en plaque (SEP) à partir du Système National des Données de Santé (SNDS). Revue Neurologique [Internet], s81–2, Elsevier; 2020;176 (Suppl):S81-S82. [cited 2020 Sep 23]. Available from: https://www.em-consulte.com/article/1387114/alertePM
   Google Scholar
• Vermersch P, Suchet L, Colamarino R, et al. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017. Mult Scler Relat Disord. 2020;46:102521.
   PubMed Web of Science ®Google Scholar
• Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, et al. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162.
   PubMed Web of Science ®Google Scholar
• World Health Organization, editor. The world health report 2000: health systems: improving performance. Geneva: WHO; 2000.
   Google Scholar